Dialyser reuse-associated mortality and hospitalization risk in incident Medicare haemodialysis patients, 1998-1999

Nephrology Dialysis Transplantation

Volumn 19, Issue 5, 2004, Pages 1245-1251

  Collins, Allan J ^a,b   Liu, Jiannong ^a   Ebben, James P ^a  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

Chronic kidney failure; Morbidity; Mortality; Renal dialysis

Indexed keywords

BLEACHING AGENT; FORMALDEHYDE; GLUTARALDEHYDE;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CLEANING; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; HYPOTHESIS; INSTRUMENT STERILIZATION; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECYCLING; REGRESSION ANALYSIS; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EQUIPMENT REUSE; HOSPITALIZATION; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MEDICARE; REGRESSION ANALYSIS; RENAL DIALYSIS; SURVIVAL ANALYSIS; UNITED STATES;

EID: 2442438769     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh011     Document Type: Article

References (24)

1. U.S. Renal Data System. USRDS 2002 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2002
2. Held PJ, Wolfe RA, Gaylin DS et al. Analysis of the association of dialyzer reuse practices and patient outcomes. Am J Kidney Dis 1994; 23: 692-708
3. Feldman HI, Kinosian M, Bilker WB et al. Effect of dialyzer reuse on survival of patients treated with hemodialysis. J Am Med Assoc 1996; 276: 620-625
4. Collins AJ, Ma J, Constantini E, Everson S. Dialysis unit and patient characteristics associated with reuse practices and mortality: 1989-1993. J Am Soc Nephrol 1998; 9: 2108-2117
5. Ebben JP, Dalleska F, Ma JZ et al. Impact of disease severity and hematocrit level on reuse-associated mortality. Am J Kidney Dis 2000; 35: 244-249
6. Leypoldt JK, Cheung AK, Deeter RB. Effect of hemodialyzer reuse: dissociation between clearances of small and large solutes. Am J Kidney Dis 1998; 32: 295-301
7. Ouseph R, Smith BP, Ward RA. Maintaining blood compartment volume in dialyzers reprocessed with peracetic acid maintains Kt/V but not B2-microglobulin removal. Am J Kidney Dis 1997; 30: 501-506
8. DiRaimondo CR, Pollak VE. Beta 1-microglobulin kinetics in maintenance hemodialysis: a comparison of conventional and high-flux dialyzers and the effects of dialyzer reuse. Am J Kidney Dis 1989; 13: 390-395
9. Port FK, Wolfe RA, Hulbert-Shearon TE et al. Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: results from the USRDS dialysis morbidity and mortality study. Am J Kidney Dis 2001; 37: 276-286
10. Eknoyan G, Levin N. Clinical Practice Guidelines: Final Guideline Summaries from the Work Groups of the National Kidney Foundation - Dialysis Outcomes Quality Initiative. National Kidney Foundation, New York, 1997
11. Collins AJ, Li S, St.Peter WL et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12: 2465-2473
12. Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol 2000; 20: 345-349
13. Collins AJ, Li S, Ebben J, Ma JZ, Manning W. Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis 2000; 36: 282-293
14. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 2000; 15: 1207-1211
15. Panichi V, Migliori M, De Pietro S et al. Plasma C-reactive protein in hemodialysis patients: a cross-sectional, longitudinal clinical survey. Blood Purif 2000; 18: 30-36
16. Nieken J, Mulder NH, Buter J et al. Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood 1995; 86: 900-905
17. Tokars J, Miller ER, Alter M, Arduino M. National Surveillance of Dialysis-Associated Diseases in the United States, 1997 (Report). Centers for Disease Control and Prevention, Atlanta, GA, 1998
18. Umen AJ, Le C. Prognostic factors, models and related statistical problems in the survival of end-stage renal disease patients on hemodialysis. Stat Med 1986; 5: 637-652
19. Cheung AK, Agodoa LY, Daugirdas JT et al. Effects of hemodialyzer reuse on clearances of urea and B2-microglobulin. J Am Soc Nephrol 1999; 10: 117-127
20. Scott MK, Mueller BA, Sowinski KM, Clark WR. Dialyzer-dependent changes in solute and water permeability with bleach reprocessing. Am J Kidney Dis 1999; 33: 87-96
21. Centers for Medicare and Medicaid Services. 2001 Annual Report, End Stage Renal Disease Clinical Performance Measures Project. Department of Health and Human Services, Centers for Medicare and Medicaid Services, Center for Beneficiary Choices, Baltimore, MD, 2001
22. Gilbertson DT, Unruh M, McBean AM et al. Influenza vaccine delivery and effectiveness in end-stage renal disease. Kidney Int 2003; 63: 738-743
23. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019
24. Ebben J, Liu J, Collins AJ. Do patients treated with low-flux polysulfone dialyzers have better outcomes than those patients treated with high-flux reused dialyzers in 1998-1999? (Abstract). J Am Soc Nephrol 2002; 13: 614A